Physicians' Academy for Cardiovascular Education

CETP inhibition

Follow the news of this evolving novel class of LDL-c lowering agents

What have we learned from previous CETP inhibitor outcome trials?

10' education - Sep. 15, 2022 - Prof. Stephen Nicholls, MD

Lessons from the biology of CETP inhibition

10' education - Aug. 2, 2022 - Prof. John Kastelein, MD, PhD

New oral therapy of CETP inhibition for lipid lowering

3' education - May 24, 2022 - Prof. Kausik Ray, MD

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD

Moving from ignorance on the complexity of HDL to novel therapeutic opportunities

3' education - June 3, 2019 - John Chapman, DSc

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA

REVEALing where we stand with HDL

10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA

First time CV reduction is achieved with CETP inhibition

3' education - Aug. 29, 2017

Natural randomisation shows that mode of LDL-lowering determines CV benefit

3' education - Aug. 28, 2017

HDL: moving forward after disappointing results with HDL-mimetic in CARAT study.

10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia
##SCROLLER_ITEMS_FULL_TITLE##

ACCELERATE: No reduction of major CV events with CETP inhibition

3' education - Apr. 7, 2016 - ACC, Chicago 2016 - Stephen J. Nicholls, MD, PhD
##SCROLLER_ITEMS_FULL_TITLE##

2014: the major lipid developments in review

3' education - Dec. 20, 2014 - Amsterdam - Prof. John JP Kastelein
##SCROLLER_ITEMS_FULL_TITLE##

CETP inhibition: Confusion, conflicting results but promising developments

3' education - Oct. 3, 2014 - Snapshot 2014 - Prof Philip Barter
##SCROLLER_ITEMS_FULL_TITLE##

CETP inhibition: Close to a better understanding of the promise?

10' education - Sep. 4, 2014 - Snapshot 2014 - Prof. Philip Barter, Sydney, Australia
##SCROLLER_ITEMS_FULL_TITLE##

Options left for HDL therapies

3' education - Oct. 3, 2013 - Snapshot 2013 - Bryan Brewer

What have we learned from previous CETP inhibitor outcome trials?

10' education - Sep. 15, 2022 - Prof. Stephen Nicholls, MD
Prof. Nicholls reviews what we have learned from previous studies with different CETP inhibitors, and presents details about ongoing studies with the CETP inhibitor obicetrapib.

Prof. Nicholls reviews what we have learned from previous studies with different CETP inhibitors, and presents details about studies with the ongoing CETP inhibitor obicetrapib.

Lessons from the biology of CETP inhibition

10' education - Aug. 2, 2022 - Prof. John Kastelein, MD, PhD

"It has become apparent that the reduction in atherogenic lipoproteins drives CHD protection by CETP inhibition - not changes in HDL-c", says Prof. Kastelein. He explains this statement by findings from studies.

CETP inhibitor reduces LDL-c on top of high-intensity statin

News - May 24, 2022

EAS 2022 Treatment with the CETP inhibitor obicetrapib resulted in a dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.

New oral therapy of CETP inhibition for lipid lowering

3' education - May 24, 2022 - Prof. Kausik Ray, MD
Prof. Ray shares the topline results of the ROSE trial, in which the effect of obicetrapib was examined in patients with elevated LDL-c despite high-intensity statin treatment.

EAS 2022 Prof. Ray shares the topline results of the ROSE trial, in which the effect of obicetrapib was examined in patients with elevated LDL-c despite high-intensity statin treatment.

Biology of CETP inhibition

The Biology of CETP inhibition

Slides (curriculum) - Feb. 3, 2022
The Biology of CETP inhibition

Educational slides on the emerging role of CETP inhibition in the management of cardiovascular disease

Larger benefit of CETP inhibitor with longer follow-up

Literature - Dec. 22, 2021 - HPS3/TIMI55-REVEAL Collaborative group - Eur Heart J. 2021

The benefit of the CETP inhibitor anacetrapib on major coronary events increases with longer follow-up, shown in a post-trial analysis of patients who had been randomized to anacetrapib compared to those on placebo in the REVEAL trial.

Dose-dependent reduction of LDL-c levels by CETP-inhibitor

News - Nov. 29, 2021
Treatment with the CETP inhibitor obicetrapib resulted in dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.

AHA 2021 Treatment with the CETP inhibitor obicetrapib resulted in dose-dependent reduction of LDL-c after 8 weeks in patients enrolled in the ROSE trial. Obicetrapib had a good safety and tolerability profile.

Lipids beyond LDL-c: HDL-c and triglycerides

5' education - Feb. 25, 2020 - Prof. Peter Libby, MD
There has been confusion about the relationship between HDL-c and CV risk in the past and also between triglycerides and CV risk. Prof. Libby gives an update on what we know now about these lipids and CV risk.

In the past, there has been confusion about the relationship between HDL-c and CV risk and also between triglycerides and CV risk. Prof. Libby gives an update on what we know now about these lipids and CV risk.

Moving from ignorance on the complexity of HDL to novel therapeutic opportunities

EAS 2019 - Maastricht, The Netherlands

3' education - June 3, 2019 - John Chapman, DSc
Emerging evidence reveals that

EAS 2019 Emerging evidence reveals that "HDL" represents an enormously heterogeneous mixture of particles, with varying structural, compositional, metabolic and functional properties.

Clinical interest in HDL is historically low, but research into HDL never stopped. With interesting results

News - May 30, 2019
Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

EAS 2019 Prof. Chapman is convinced that better understanding of HDL metabolism can lead to novel therapies, but we need to realize that it is much more complex than we have acknowledged thus far.

Reduction of CV risk with CETP inhibition may be due to a specific reduction of small VLDL

Literature - Nov. 26, 2018 - Blauw LL et al. - Eur J Hum Genet 2018

A Mendelian randomization study combined with metabolic biomarker analysis shows that CETP is an important causal determinant of HDL and VLDL concentration and composition.

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA
Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c.. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.

VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.

CETP inhibition